US biotech Biohaven last week received a commitment from Oberland Capital to invest up to $600 million in the company. Also, ...

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

Officials with Arvinas, a New Haven-based biotechnology firm, announced Thursday that the company is laying off 131 workers at the end of June, including 92 in Connecticut. The company announced its ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, ...

Shares of US clinical-stage biotech Biohaven (NYSE: BHVN) rose 9.6% to $21.74 yesterday, after it announced an agreement with ...

The biotech has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its spinocerebellar ...

Oberland Capital Management is pumping some new life into Biohaven, striking a unique investment deal worth up to $600 ...

Shares of Biohaven ( BHVN 5.24%) are surging on Monday. The company's stock was up about 8% as of midday trading and had ...

Biohaven Ltd. (BHVN) shares rise premarket as it secures up to $600 million investment from Oberland Capital. Cash reserves ...

Biohaven will receive up to $600 million to support ongoing clinical trials and the full development of its portfolio.